Progenitor Cell Line (hPheo1) Derived from a Human Pheochromocytoma Tumor

Background Pheochromocytomas are rare tumors generally arising in the medullary region of the adrenal gland. These tumors release excessive epinephrine and norepinephrine resulting in hypertension and cardiovascular crises for which surgery is the only definitive treatment. Molecular mechanisms that control tumor development and hormone production are poorly understood, and progress has been hampered by the lack of human cellular model systems. To study pheochromocytomas, we developed a stable progenitor pheochromocytoma cell line derived from a primary human tumor. Methods After IRB approval and written informed consent, human pheochromocytoma tissue was excised, minced, dispersed enzymatically, and cultured in vitro. Primary pheochromocytoma cells were infected with a lentivirus vector carrying the catalytic subunit of human telomerase reverse transcriptase (hTERT). The hTERT immortalized cells (hPheo1) have been passaged >300 population doublings. The resulting cell line was characterized morphologically, biochemically and for expression of neuroendocrine properties. The expression of marker enzymes and proteins was assessed by immunofluorescence staining and immunoblotting. Telomerase activity was determined by using the telomeric repeat amplification protocol (TRAP) assay. Results We have established a human pheochromocytoma precursor cell line that expresses the neuroendocrine marker, chromogranin A, when differentiated in the presence of bone morphogenic protein 4 (BMP4), nerve growth factor (NGF), and dexamethasone. Phenylethanolamine N-methyltransferase (PNMT) expression is also detected with this differentiation regimen. CD-56 (also known as NCAM, neural cell adhesion molecule) is expressed in these cells, but CD31 (also known as PECAM-1, a marker of endothelial cells) is negative. Conclusions We have maintained hTERT-immortalized progenitor cells derived from a pheochromocytoma (hPheo1) in culture for over 300 population doublings. This progenitor human cell line is normal diploid except for a deletion in the p16 region and has inducible neuroendocrine biomarkers. These cells should be a valuable reagent for studying mechanisms of tumor development and for testing novel therapeutic approaches.

[1]  Electron Kebebew,et al.  Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. , 2012, The New England journal of medicine.

[2]  J. Benítez,et al.  Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma , 2011, Nature Genetics.

[3]  Luc Girard,et al.  Lung cancer cell lines as tools for biomedical discovery and research. , 2010, Journal of the National Cancer Institute.

[4]  Patricia L. M. Dahia,et al.  Germline mutations in TMEM127 confer susceptibility to pheochromocytoma , 2010, Nature Genetics.

[5]  E. Maher,et al.  The Telomerase Antagonist, Imetelstat, Efficiently Targets Glioblastoma Tumor-Initiating Cells Leading to Decreased Proliferation and Tumor Growth , 2010, Clinical Cancer Research.

[6]  J. Shay,et al.  H-Ras Expression in Immortalized Keratinocytes Produces an Invasive Epithelium in Cultured Skin Equivalents , 2009, PloS one.

[7]  W. Huttner,et al.  Isolation of Neural Crest Derived Chromaffin Progenitors from Adult Adrenal Medulla , 2009, Stem cells.

[8]  Steven P. Gygi,et al.  SDH5, a Gene Required for Flavination of Succinate Dehydrogenase, Is Mutated in Paraganglioma , 2009, Science.

[9]  H. Lehnert,et al.  Treatment of Malignant Pheochromocytoma , 2009, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[10]  R. deLeeuw,et al.  Array-comparative genomic hybridization in sporadic benign pheochromocytomas. , 2009, Endocrine-related cancer.

[11]  A. Tischler,et al.  Characterization of an animal model of aggressive metastatic pheochromocytoma linked to a specific gene signature , 2009, Clinical & Experimental Metastasis.

[12]  A. Evans,et al.  Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. , 2009, The Journal of clinical endocrinology and metabolism.

[13]  K. Wyne,et al.  The many faces of pheochromocytoma , 2008, Journal of endocrinological investigation.

[14]  Yang Xie,et al.  Enhanced identification and biological validation of differential gene expression via Illumina whole-genome expression arrays through the use of the model-based background correction methodology , 2008, Nucleic acids research.

[15]  W. Frankel,et al.  Expression of the p16INK4A/Cdkn2a gene is prevalently downregulated in human pheochromocytoma tumor specimens. , 2008, Gene expression.

[16]  E. Korpershoek,et al.  Expression of activin and inhibin subunits, receptors and binding proteins in human pheochromocytomas: a study based on mRNA analysis and immunohistochemistry , 2007, Clinical endocrinology.

[17]  R. Ashfaq,et al.  Telomerase immortalization of human mammary epithelial cells derived from a BRCA2 mutation carrier , 2006, Breast Cancer Research and Treatment.

[18]  C. Larsson,et al.  Pheochromocytoma and functional paraganglioma syndrome: No longer the 10% tumor , 2005, Journal of surgical oncology.

[19]  J. Pollack,et al.  Immortalization of Human Bronchial Epithelial Cells in the Absence of Viral Oncoproteins , 2004, Cancer Research.

[20]  A. Tischler,et al.  Pheochromocytoma cell lines from heterozygous neurofibromatosis knockout mice , 2000, Cell and Tissue Research.

[21]  D. Hauri,et al.  Pheochromocytomas: can malignant potential be predicted? , 1999, Urology.

[22]  B. Ponder,et al.  First continuous human pheochromocytoma cell line: KNA Biological, cytogenetic and molecular characterization of KNA cells , 1998, Journal of neurocytology.

[23]  C. Harley,et al.  Extension of life-span by introduction of telomerase into normal human cells. , 1998, Science.

[24]  R. Aguiar,et al.  Deletion analysis of the p16 tumour suppressor gene in phaeochromocytomas , 1996, Clinical endocrinology.

[25]  A. Saltiel,et al.  Nerve Growth Factor Stimulates the Tyrosine Phosphorylation of Endogenous Crk-II and Augments Its Association with p130 in PC-12 Cells (*) , 1996, The Journal of Biological Chemistry.

[26]  S. Mills,et al.  Immunohistochemical detection of neuroblastomatous foci in composite adrenal pheochromocytoma-neuroblastoma. , 1994, American journal of clinical pathology.

[27]  I. Ernest,et al.  Long-term results in 64 patients operated upon for pheochromocytoma. , 2009, Acta medica Scandinavica.

[28]  A. Gazdar,et al.  Correspondence re: Martin Brower et al. Growth of Cell Lines and Clinical Specimens of Human Non-Small Cell Lung Cancer in a Serum-free Defined Medium. Cancer Res., 46: 798–806, 1986 , 1986 .

[29]  J. Minna,et al.  Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium. , 1986, Cancer research.

[30]  A. Gazdar,et al.  Re: Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium. , 1986, Cancer research.

[31]  L. Greene,et al.  Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Tait,et al.  The properties of adrenal zona glomerulosa cells after purification by gravitational sedimentation , 1974, Proceedings of the Royal Society of London. Series B. Biological Sciences.

[33]  J. Tait,et al.  In vitro effects of ACTH, angiotensins, serotonin and potassium on steroid output and conversion of corticosterone to aldosterone by isolated adrenal cells. , 1970, Endocrinology.